Oxular appoints Jane Bridgman as Vice President, Operations

- Jane Bridgman joins Oxular from Allergan
- Jane has more than 18 years' operations experience in ophthalmology

1 April 2017 – Oxular Limited, the retinal therapeutics company, today announces the appointment of Jane Bridgman as Vice President, Operations. Jane will be responsible for managing day-to-day operations and clinical activities.

Jane brings more than 18 years' operations experience in drug development, including an extensive background in ophthalmology. Jane was Director, Clinical Operations, Ophthalmology at Allergan where she served for more than 10 years in escalating roles of responsibility and lead multiple clinical programs for both ophthalmic drug and device products. Most recently, Jane was responsible for managing Allergan's European Ophthalmology team as well as its Global Program operations for a suite of large studies for Abicipar, Allergan's late stage anti-VEGF therapy.

Previously, Jane worked in clinical operations roles in oncology, pediatrics, cardiology at Eli Lilly and Roche.

Tom Cavanagh, CEO of Oxular commented:

"We are delighted to welcome Jane to the Oxular team. Jane's considerable experience in drug development operations and her strong background in ophthalmology will be a great asset to the Company as we advance our pipeline of innovate retinal treatments through development."

Enquiries

FTI Consulting
Ben Atwell

Tel: +44 (0)2037 271390

About Oxular Limited

Oxular is developing novel retinal treatments engineered to access specific small spaces in the eye and to provide unique drug distribution to tissues specifically involved in retinal diseases. The innovative approach aims to increase therapeutic effectiveness, reduce side-effects and minimize frequency of treatments. Oxular's product development pipeline includes treatments for both prevalent retinal diseases, such as age diabetic macular edema, as well as rare and orphan indications (www.oxular.com).

